PET study shows promising results for antipsychotic drug

12/21/2009 | PR Newswire

A Phase I PET study showed Intra-Cellular Therapies' experimental antipsychotic drug ITI-007 interacted with key targets in the living human brain, a mechanism that will influence drug action. "We believe that these results will translate into a reduced need to impose high doses of drugs on patients suffering from schizophrenia and other disorders," CEO Sharon Mates said.

View Full Article in:

PR Newswire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL